TY  - JOUR
A1  - Müller-Thomas, Catharina
A1  - Rudelius, Martina
A1  - Rondak, Ina-Christine
A1  - Haferlach, Torsten
A1  - Schanz, Julie
A1  - Huberle, Christina
A1  - Schmidt, Burkard
A1  - Blaser, Rainer
A1  - Kremer, Marcus
A1  - Peschel, Christian
A1  - Germing, Ulrich
A1  - Platzbecker, Uwe
A1  - Goetze, Katharina
T1  - Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia
JF  - HAEMATOLOGICA
N2  - No abstract available.
KW  - TP53 mutations
KW  - DEL(5Q)
KW  - MDS
KW  - p53 expression
KW  - azacitidine
KW  - scoring system
KW  - prognosis
KW  - karyotype
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-115313
SN  - 1592-8721
VL  - 99
IS  - 10
ER  - 
TY  - JOUR
A1  - Kimpel, Otilia
A1  - Schindler, Paul
A1  - Schmidt-Pennington, Laura
A1  - Altieri, Barbara
A1  - Megerle, Felix
A1  - Haak, Harm
A1  - Pittaway, James
A1  - Dischinger, Ulrich
A1  - Quinkler, Marcus
A1  - Mai, Knut
A1  - Kroiss, Matthias
A1  - Polat, Bülent
A1  - Fassnacht, Martin
T1  - Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma
JF  - British Journal of Cancer
N2  - Background
International guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low.

Methods
We retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000. Primary endpoint: time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predictive factors by Cox analyses.

Results
In total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50–60 Gy (n = 20) or 20–49 Gy (n = 69), stereotactic body RT of 35–50 Gy (SBRT) (n = 36), or brachytherapy of 12–25 Gy (BT) (n = 7). Best objective lesional response was complete (n = 6), partial (n = 52), stable disease (n = 60), progressive disease (n = 14). Median tTTP was 7.6 months (1.0–148.6). In comparison to cRT\(_{20-49Gy}\), tTTP was significantly longer for cRT\(_{50-60Gy}\) (multivariate adjusted HR 0.10; 95% CI 0.03–0.33; p < 0.001) and SBRT (HR 0.31; 95% CI 0.12–0.80; p = 0.016), but not for BT (HR 0.66; 95% CI 0.22–1.99; p = 0.46). Toxicity was generally mild and moderate with three grade 3 events. No convincing predictive factors could be established.

Conclusions
This largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC.
KW  - adrenal tumours
KW  - adrenocortical carcinoma (ACC)
KW  - radiotherapy (RT)
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324411
VL  - 128
IS  - 4
ER  - 
TY  - JOUR
A1  - Merzenich, Hiltrud
A1  - Baaken, Dan
A1  - Schmidt, Marcus
A1  - Bekes, Inga
A1  - Schwentner, Lukas
A1  - Janni, Wolfgang
A1  - Woeckel, Achim
A1  - Bartkowiak, Detlef
A1  - Wiegel, Thomas
A1  - Blettner, Maria
A1  - Wollschläger, Daniel
A1  - Schmidberger, Heinz
T1  - Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)
JF  - Breast Cancer Research and Treatment
N2  - Purpose
Radiotherapy (RT) was identified as a risk factor for long-term cardiac effects in breast cancer patients treated until the 1990s. However, modern techniques reduce radiation exposure of the heart, but some exposure remains unavoidable. In a retrospective cohort study, we investigated cardiac mortality and morbidity of breast cancer survivors treated with recent RT in Germany.

Methods
A total of 11,982 breast cancer patients treated between 1998 and 2008 were included. A mortality follow-up was conducted until 06/2018. In order to assess cardiac morbidity occurring after breast cancer treatment, a questionnaire was sent out in 2014 and 2019. The effect of breast cancer laterality on cardiac mortality and morbidity was investigated as a proxy for radiation exposure. We used Cox Proportional Hazards regression analysis, taking potential confounders into account.

Results
After a median follow-up time of 11.1 years, there was no significant association of tumor laterality with cardiac mortality in irradiated patients (hazard ratio (HR) for left-sided versus right-sided tumor 1.09; 95% confidence interval (CI) 0.85–1.41). Furthermore, tumor laterality was not identified as a significant risk factor for cardiac morbidity (HR = 1.05; 95%CI 0.88–1.25).

Conclusions
Even though RT for left-sided breast cancer on average incurs higher radiation dose to the heart than RT for right-sided tumors, we found no evidence that laterality is a strong risk factor for cardiac disease after contemporary RT. However, larger sample sizes, longer follow-up, detailed information on individual risk factors and heart dose are needed to assess clinically manifest late effects of current cancer therapy.
KW  - breast cancer
KW  - 3D-conformal radiotherapy
KW  - cardiac mortality
KW  - cardiac morbidity
KW  - cohort study
KW  - survival
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-308606
SN  - 0167-6806
SN  - 1573-7217
VL  - 191
IS  - 1
ER  -